Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan.
Int Urol Nephrol. 2022 Jan;54(1):63-69. doi: 10.1007/s11255-021-03005-3. Epub 2021 Nov 16.
The prognosis of patients undergoing 2-sided radical nephroureterectomies (RNUs) with a residual bladder due to bilateral upper tract urothelial carcinoma (UTUC) is poorly understood. This study was aimed toward surveying the oncology outcomes and prognostic factors that may help in shared decision-making related to bladder preservation in patients preparing to receive 2-sided RNUs.
Patients with synchronous or metachronous bilateral UTUC who received bilateral RNUs with a residual bladder in our hospital were retrospectively reviewed. Clinical and pathological data were analyzed for potential variables affecting the oncology outcomes.
A total of 50 patients were included. The average age at completion of the 2-sided RNU was 62.7 ± 12.4 years, with a mean follow-up of 88.4 ± 59.3 months after the 2-sided RNUs. The medium overall survival was 13.4 ± 1.8 years. Twenty-six patients (52%) had cancer recurrence in the residual bladder, but only 2 (8%) of the recurrences were muscle invasive. The highest UTUC stage was the only predictive factor for cancer-specific survival (CSS) rather than intravesical recurrence. The 5 year CSS rates in patients with the highest UTUC stage ≦ pT2 and ≧ pT3 were 90% and 51%, respectively (p = 0.007).
Risk of cancer recurrence in the residual bladder is high, but does not affect survival outcomes. The highest UTUC stage plays a significant role in cancer-specific survival. With a careful patient surveillance, bladder preservation may be reasonable in patients with bilateral UTUC preparing for 2-sided RNUs.
由于双侧上尿路尿路上皮癌(UTUC),接受双侧根治性肾输尿管切除术(RNUs)并保留膀胱的患者的预后情况了解甚少。本研究旨在调查肿瘤学结果和可能有助于在准备接受双侧 RNUs 的患者中进行膀胱保留相关的决策制定的预后因素。
回顾性分析了在我院接受双侧 RNUs 并保留膀胱的同步或异时性双侧 UTUC 患者的临床和病理资料,分析了可能影响肿瘤学结果的潜在变量。
共纳入 50 例患者。完成双侧 RNU 的平均年龄为 62.7 ± 12.4 岁,双侧 RNUs 后平均随访 88.4 ± 59.3 个月。中位总生存期为 13.4 ± 1.8 年。26 例(52%)患者在残留膀胱中出现癌症复发,但仅有 2 例(8%)复发为肌层浸润性。最高 UTUC 分期是唯一预测癌症特异性生存(CSS)的因素,而不是膀胱内复发。最高 UTUC 分期 ≦ pT2 和 ≧ pT3 的患者 5 年 CSS 率分别为 90%和 51%(p=0.007)。
残留膀胱中癌症复发的风险较高,但不会影响生存结果。最高 UTUC 分期在癌症特异性生存中起重要作用。对双侧 UTUC 患者进行仔细的患者监测后,双侧 RNUs 并保留膀胱可能是合理的。